Unity Biotechnology Past Earnings Performance
Past criteria checks 0/6
Unity Biotechnology has been growing earnings at an average annual rate of 13%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 39.2% per year.
Key information
13.0%
Earnings growth rate
33.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 39.2% |
| Return on equity | -140.4% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Here's Why We're A Bit Worried About Unity Biotechnology's (NASDAQ:UBX) Cash Burn Situation
Mar 05
Companies Like Unity Biotechnology (NASDAQ:UBX) Could Be Quite Risky
Nov 18UNITY Biotechnology falls 7% on reverse stock split
Oct 19Unity Biotechnology cuts stock sales agreement in half to $25M
Aug 19Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M
Aug 12A Look At Unity's UBX1325 Phase 1 Results
Jul 26Trade Alert: The Co-Founder Of Unity Biotechnology, Inc. (NASDAQ:UBX), Nathaniel David, Has Sold Some Shares Recently
Dec 22A Look Inside Unity Bio's Transition To An Ophthalmology Company
Nov 27Revenue & Expenses BreakdownBeta
How Unity Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -40 | 19 | 0 |
| 30 Sep 23 | 0 | -53 | 20 | 0 |
| 30 Jun 23 | 0 | -51 | 21 | 0 |
| 31 Mar 23 | 0 | -52 | 19 | 0 |
| 31 Dec 22 | 0 | -44 | 20 | 0 |
| 30 Sep 22 | 5 | -56 | 21 | 0 |
| 30 Jun 22 | 5 | -59 | 22 | 0 |
| 31 Mar 22 | 5 | -64 | 23 | -9 |
| 31 Dec 21 | 5 | -61 | 23 | 0 |
| 30 Sep 21 | 0 | -70 | 23 | -54 |
| 30 Jun 21 | 0 | -81 | 24 | -35 |
| 31 Mar 21 | 0 | -82 | 24 | -11 |
| 31 Dec 20 | 0 | -94 | 24 | 0 |
| 30 Sep 20 | 0 | -92 | 24 | 125 |
| 30 Jun 20 | 0 | -86 | 23 | 106 |
| 31 Mar 20 | 0 | -91 | 22 | 90 |
| 31 Dec 19 | 0 | -82 | 20 | 0 |
| 30 Sep 19 | 0 | -86 | 19 | 0 |
| 30 Jun 19 | 0 | -83 | 18 | 0 |
| 31 Mar 19 | 0 | -79 | 17 | 0 |
| 31 Dec 18 | 0 | -76 | 16 | 59 |
| 30 Sep 18 | 1 | -67 | 14 | 0 |
| 30 Jun 18 | 1 | -60 | 12 | 0 |
| 31 Mar 18 | 1 | -52 | 11 | 0 |
| 31 Dec 17 | 1 | -45 | 10 | 0 |
Quality Earnings: UBX is currently unprofitable.
Growing Profit Margin: UBX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: UBX is unprofitable, but has reduced losses over the past 5 years at a rate of 13% per year.
Accelerating Growth: Unable to compare UBX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UBX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: UBX has a negative Return on Equity (-140.36%), as it is currently unprofitable.